Aimmune Therapeutics, Inc.
13
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
15.4%
2 terminated/withdrawn out of 13 trials
83.3%
-3.2% vs industry average
62%
8 trials in Phase 3/4
120%
12 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Aimmune Longitudinal Collaboration Study
Role: lead
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
Role: lead
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Role: collaborator
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Role: lead
PALISADE Follow-on Study (ARC004)
Role: lead
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Role: lead
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Role: lead
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
Role: lead
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
Role: lead
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Role: lead
AR101 Real-World Open-Label Extension Study
Role: lead
ARTEMIS Peanut Allergy In Children
Role: lead
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
Role: lead
All 13 trials loaded